$BNTX (-3,32 %) BioNTech - Jeffries upgrades the price target for the 2nd time within a few days. The price target was raised from 96 to 150 dollars. This implies a return potential of over 21% compared to Monday's closing price.
The analyst is modeling risk-adjusted peak sales of 3.6 billion euros for BNT327 and raised his estimate due to the increased conviction regarding the future of the drug.
